Do analysts recommend ONCY or INDP?

Oncolytics Biotech presently has a consensus price target of $5.00, indicating a potential upside of 829.02%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Oncolytics Biotech is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncolytics Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, ONCY or INDP?

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncolytics Biotech N/A N/A -$28.76M -$0.34 N/A Indaptus Therapeutics N/A N/A -$20.85M -$6.33 N/A

Is ONCY or INDP more profitable?

Oncolytics Biotech's return on equity of 0.00% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oncolytics Biotech N/A N/A -442.99% Indaptus Therapeutics N/A -302.89% -203.49%

Which has preferable earnings & valuation, BNTC or ONCY?

Benitec Biopharma is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Benitec Biopharma N/A N/A -$45.55M -$0.98 N/A Oncolytics Biotech N/A N/A -$28.76M -$0.34 N/A

Is BNTC or ONCY more profitable?

Oncolytics Biotech's return on equity of 0.00% beat Benitec Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Benitec Biopharma N/A -28.41% -27.76% Oncolytics Biotech N/A N/A -442.99%

Does the media prefer BNTC or ONCY?

In the previous week, Oncolytics Biotech had 4 more articles in the media than Benitec Biopharma. MarketBeat recorded 8 mentions for Oncolytics Biotech and 4 mentions for Benitec Biopharma. Oncolytics Biotech's average media sentiment score of 1.12 beat Benitec Biopharma's score of 0.56 indicating that Oncolytics Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ONCY or BBOT?

Oncolytics Biotech is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncolytics Biotech N/A N/A -$28.76M -$0.34 N/A BridgeBio Oncology Therapeutics N/A N/A -$134.04M -$2.76 N/A

Is ONCY or BBOT more profitable?

Oncolytics Biotech's return on equity of 0.00% beat BridgeBio Oncology Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oncolytics Biotech N/A N/A -442.99% BridgeBio Oncology Therapeutics N/A -46.90% -42.17%

Does the media refer more to ONCY or BBOT?

In the previous week, Oncolytics Biotech had 4 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 8 mentions for Oncolytics Biotech and 4 mentions for BridgeBio Oncology Therapeutics. Oncolytics Biotech's average media sentiment score of 1.12 beat BridgeBio Oncology Therapeutics' score of 0.70 indicating that Oncolytics Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncolytics Biotech 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Oncology Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, AGMB or ONCY?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Oncolytics Biotech N/A N/A -$28.76M -$0.34 N/A

Is AGMB or ONCY more profitable?

Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Oncolytics Biotech N/A N/A -442.99%

Does the media refer more to AGMB or ONCY?

In the previous week, AgomAb Therapeutics had 2 more articles in the media than Oncolytics Biotech. MarketBeat recorded 10 mentions for AgomAb Therapeutics and 8 mentions for Oncolytics Biotech. AgomAb Therapeutics' average media sentiment score of 1.17 beat Oncolytics Biotech's score of 1.12 indicating that AgomAb Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, LRMR or ONCY?

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Larimar Therapeutics N/A N/A -$165.67M -$1.95 N/A Oncolytics Biotech N/A N/A -$28.76M -$0.34 N/A

Is LRMR or ONCY more profitable?

Oncolytics Biotech's return on equity of 0.00% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -137.39% -97.65% Oncolytics Biotech N/A N/A -442.99%

Does the media prefer LRMR or ONCY?

In the previous week, Oncolytics Biotech had 6 more articles in the media than Larimar Therapeutics. MarketBeat recorded 8 mentions for Oncolytics Biotech and 2 mentions for Larimar Therapeutics. Oncolytics Biotech's average media sentiment score of 1.12 beat Larimar Therapeutics' score of 0.91 indicating that Oncolytics Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oncolytics Biotech (ONCY) Competitors

$0.54 +0.05 (+9.84%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$0.54 +0.00 (+0.52%)

As of 10/14/2026 07:56 PM Eastern

Compare

ONCY vs. INDP, BNTC, BBOT, AGMB, and LRMR

Should you buy Oncolytics Biotech stock or one of its competitors? Oncolytics Biotech's main competitors and comparable companies include Indaptus Therapeutics (INDP), Benitec Biopharma (BNTC), BridgeBio Oncology Therapeutics (BBOT), AgomAb Therapeutics (AGMB), and Larimar Therapeutics (LRMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oncolytics Biotech compare to Indaptus Therapeutics?

Oncolytics Biotech (NASDAQ:ONCY) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Oncolytics Biotech has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 4.7% of Oncolytics Biotech shares are owned by company insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Oncolytics Biotech had 7 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 8 mentions for Oncolytics Biotech and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.79 beat Oncolytics Biotech's score of 1.12 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncolytics Biotech	Positive
Indaptus Therapeutics	Very Positive

Oncolytics Biotech presently has a consensus price target of $5.00, indicating a potential upside of 829.02%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Oncolytics Biotech is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Oncolytics Biotech's return on equity of 0.00% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	N/A	-442.99%
Indaptus Therapeutics	N/A	-302.89%	-203.49%

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A

Summary

Oncolytics Biotech beats Indaptus Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Oncolytics Biotech compare to Benitec Biopharma?

Benitec Biopharma (NASDAQ:BNTC) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Benitec Biopharma presently has a consensus target price of $24.00, indicating a potential upside of 189.51%. Oncolytics Biotech has a consensus target price of $5.00, indicating a potential upside of 829.02%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Benitec Biopharma is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$45.55M	-$0.98	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A

In the previous week, Oncolytics Biotech had 4 more articles in the media than Benitec Biopharma. MarketBeat recorded 8 mentions for Oncolytics Biotech and 4 mentions for Benitec Biopharma. Oncolytics Biotech's average media sentiment score of 1.12 beat Benitec Biopharma's score of 0.56 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Benitec Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncolytics Biotech	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oncolytics Biotech's return on equity of 0.00% beat Benitec Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-28.41%	-27.76%
Oncolytics Biotech	N/A	N/A	-442.99%

Benitec Biopharma has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 4.8% of Benitec Biopharma shares are held by company insiders. Comparatively, 4.7% of Oncolytics Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Oncolytics Biotech beats Benitec Biopharma on 10 of the 14 factors compared between the two stocks.

How does Oncolytics Biotech compare to BridgeBio Oncology Therapeutics?

Oncolytics Biotech (NASDAQ:ONCY) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Oncolytics Biotech has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

Oncolytics Biotech is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A

In the previous week, Oncolytics Biotech had 4 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 8 mentions for Oncolytics Biotech and 4 mentions for BridgeBio Oncology Therapeutics. Oncolytics Biotech's average media sentiment score of 1.12 beat BridgeBio Oncology Therapeutics' score of 0.70 indicating that Oncolytics Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncolytics Biotech	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Oncology Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oncolytics Biotech's return on equity of 0.00% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	N/A	-442.99%
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%

6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 4.7% of Oncolytics Biotech shares are held by insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Oncolytics Biotech currently has a consensus target price of $5.00, suggesting a potential upside of 829.02%. BridgeBio Oncology Therapeutics has a consensus target price of $22.88, suggesting a potential upside of 688.79%. Given Oncolytics Biotech's higher probable upside, research analysts plainly believe Oncolytics Biotech is more favorable than BridgeBio Oncology Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Oncolytics Biotech beats BridgeBio Oncology Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Oncolytics Biotech compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, AgomAb Therapeutics had 2 more articles in the media than Oncolytics Biotech. MarketBeat recorded 10 mentions for AgomAb Therapeutics and 8 mentions for Oncolytics Biotech. AgomAb Therapeutics' average media sentiment score of 1.17 beat Oncolytics Biotech's score of 1.12 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncolytics Biotech	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Oncolytics Biotech	N/A	N/A	-442.99%

6.8% of Oncolytics Biotech shares are held by institutional investors. 4.7% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

AgomAb Therapeutics presently has a consensus target price of $37.50, indicating a potential upside of 331.53%. Oncolytics Biotech has a consensus target price of $5.00, indicating a potential upside of 829.02%. Given Oncolytics Biotech's higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than AgomAb Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

AgomAb Therapeutics and Oncolytics Biotech tied by winning 5 of the 10 factors compared between the two stocks.

How does Oncolytics Biotech compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Larimar Therapeutics currently has a consensus target price of $10.33, suggesting a potential upside of 394.42%. Oncolytics Biotech has a consensus target price of $5.00, suggesting a potential upside of 829.02%. Given Oncolytics Biotech's higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Larimar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Oncolytics Biotech had 6 more articles in the media than Larimar Therapeutics. MarketBeat recorded 8 mentions for Oncolytics Biotech and 2 mentions for Larimar Therapeutics. Oncolytics Biotech's average media sentiment score of 1.12 beat Larimar Therapeutics' score of 0.91 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncolytics Biotech	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A

Oncolytics Biotech's return on equity of 0.00% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
Oncolytics Biotech	N/A	N/A	-442.99%

91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 4.0% of Larimar Therapeutics shares are held by company insiders. Comparatively, 4.7% of Oncolytics Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Larimar Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

Summary

Oncolytics Biotech beats Larimar Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Oncolytics Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONCY vs. The Competition

Export

Metric	Oncolytics Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$64.25M	$3.84B	$7.19B	$13.18B
Dividend Yield	N/A	3.65%	2.52%	19.60%
P/E Ratio	-1.58	9.48	211.42	19.26
Price / Sales	N/A	1,168.88	565.60	77.58
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	-13.46	16.54	10.51	5.92
Net Income	-$28.76M	-$22.69M	$3.50B	$380.90M
7 Day Performance	-1.14%	-5.80%	-3.49%	-3.85%
1 Month Performance	-31.00%	-12.84%	-7.76%	-6.37%
1 Year Performance	-55.52%	3.05%	0.82%	-6.01%

Oncolytics Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONCY Oncolytics Biotech	3.0741 of 5 stars	$0.54 +9.8%	$5.00 +829.0%	-55.5%	$64.25M	N/A	N/A	29	News Coverage Positive News High Trading Volume
INDP Indaptus Therapeutics	0.8563 of 5 stars	$2.51 +5.5%	N/A	-46.9%	$317.12M	N/A	N/A	5	Positive News Gap Down
BNTC Benitec Biopharma	2.5651 of 5 stars	$9.23 +2.8%	$24.00 +160.0%	-45.0%	$313.25M	N/A	N/A	24	Gap Down High Trading Volume
BBOT BridgeBio Oncology Therapeutics	3.8971 of 5 stars	$3.60 -7.5%	$22.88 +535.4%	N/A	$311.88M	N/A	N/A	88
AGMB AgomAb Therapeutics	3.8446 of 5 stars	$8.69 +1.5%	$37.50 +331.5%	N/A	$310.19M	N/A	N/A	62

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONCY) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncolytics Biotech (ONCY) Competitors

ONCY vs. INDP, BNTC, BBOT, AGMB, and LRMR

How does Oncolytics Biotech compare to Indaptus Therapeutics?

Summary

How does Oncolytics Biotech compare to Benitec Biopharma?

Summary

How does Oncolytics Biotech compare to BridgeBio Oncology Therapeutics?

Summary

How does Oncolytics Biotech compare to AgomAb Therapeutics?

Summary

How does Oncolytics Biotech compare to Larimar Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY vs. The Competition

Oncolytics Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncolytics Biotech (ONCY) Competitors

ONCY vs. INDP, BNTC, BBOT, AGMB, and LRMR

How does Oncolytics Biotech compare to Indaptus Therapeutics?

Which has more risk & volatility, ONCY or INDP?

Do insiders & institutionals believe in ONCY or INDP?

Does the media refer more to ONCY or INDP?

Do analysts recommend ONCY or INDP?

Is ONCY or INDP more profitable?

Which has better earnings & valuation, ONCY or INDP?

Summary

How does Oncolytics Biotech compare to Benitec Biopharma?

Do analysts rate BNTC or ONCY?

Which has preferable earnings & valuation, BNTC or ONCY?

Does the media prefer BNTC or ONCY?

Is BNTC or ONCY more profitable?

Which has more volatility and risk, BNTC or ONCY?

Do insiders and institutionals believe in BNTC or ONCY?

Summary

How does Oncolytics Biotech compare to BridgeBio Oncology Therapeutics?

Which has more volatility & risk, ONCY or BBOT?

Which has preferable valuation and earnings, ONCY or BBOT?

Does the media refer more to ONCY or BBOT?

Is ONCY or BBOT more profitable?

Do insiders & institutionals have more ownership in ONCY or BBOT?

Do analysts rate ONCY or BBOT?

Summary

How does Oncolytics Biotech compare to AgomAb Therapeutics?

Does the media refer more to AGMB or ONCY?

Which has better valuation & earnings, AGMB or ONCY?

Is AGMB or ONCY more profitable?

Do institutionals & insiders believe in AGMB or ONCY?

Do analysts prefer AGMB or ONCY?

Summary

How does Oncolytics Biotech compare to Larimar Therapeutics?

Do analysts recommend LRMR or ONCY?

Does the media prefer LRMR or ONCY?

Which has preferable earnings & valuation, LRMR or ONCY?

Is LRMR or ONCY more profitable?

Do institutionals & insiders have more ownership in LRMR or ONCY?

Which has more volatility and risk, LRMR or ONCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY vs. The Competition

Oncolytics Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools